Primary Purpose
| primary_purpose | Study_Count |
|---|---|
| Treatment | 579 |
| Prevention | 278 |
| Diagnostic | 86 |
| Supportive Care | 53 |
| Basic Science | 44 |
| Other | 38 |
| Health Services Research | 35 |
| NA | 27 |
| Screening | 12 |
| Device Feasibility | 5 |
| Educational/Counseling/Training | 1 |
Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD
See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG
To return to the list of conditions and links to their rpeorts go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html
| Type | Study_count |
|---|---|
| Total_Studies | 2300 |
| interventional | 1158 |
| Observational | 1064 |
| Registry | 78 |
```
| intervention_type | Study_Count |
|---|---|
| Drug | 254 |
| Behavioral | 211 |
| Device | 146 |
| Other | 118 |
| Drug|placebo | 107 |
| Procedure | 102 |
| Behavioral|Drug | 22 |
| Diagnostic Test | 20 |
| Dietary Supplement | 20 |
| Biological | 18 |
| Drug|Procedure | 16 |
| Behavioral|Other | 12 |
| Dietary Supplement|placebo | 12 |
| Device|Drug | 11 |
| Drug|Other | 10 |
| Device|Other | 9 |
| Device|Procedure | 7 |
| Other|Procedure | 7 |
| Drug|Other|placebo | 4 |
| Behavioral|Device | 3 |
| Behavioral|Drug|placebo | 3 |
| Behavioral|Drug|Procedure | 3 |
| Behavioral|Procedure | 3 |
| Biological|placebo | 3 |
| Device|Drug|Procedure | 3 |
| Genetic | 3 |
| Behavioral|Dietary Supplement | 2 |
| Behavioral|Drug|Other | 2 |
| Diagnostic Test|Drug | 2 |
| Drug|placebo|Procedure | 2 |
| Other|placebo | 2 |
| Radiation | 2 |
| Behavioral|Biological|Drug | 1 |
| Behavioral|Device|Drug | 1 |
| Behavioral|Device|Other | 1 |
| Behavioral|Dietary Supplement|Other | 1 |
| Behavioral|Genetic | 1 |
| Behavioral|Genetic|Other | 1 |
| Biological|Device|Genetic|Procedure | 1 |
| Biological|Device|placebo | 1 |
| Biological|Drug | 1 |
| Biological|Other|placebo | 1 |
| Biological|Procedure | 1 |
| Combination Product | 1 |
| Combination Product|Device | 1 |
| Combination Product|Drug|placebo | 1 |
| Device|Other|Procedure | 1 |
| Device|Radiation | 1 |
| Diagnostic Test|Other | 1 |
| Dietary Supplement|Other | 1 |
| placebo|Procedure | 1 |
| Country | Study_Count |
|---|---|
| United States | 332 |
| NA | 234 |
| Canada | 65 |
| China | 61 |
| United Kingdom | 46 |
| Denmark | 45 |
| Germany | 35 |
| France | 32 |
| Brazil | 22 |
| Korea, Republic of | 22 |
| Sweden | 16 |
| Norway | 13 |
| Italy | 12 |
| Spain | 12 |
| Russian Federation | 11 |
| United States|Canada | 11 |
| Switzerland | 10 |
| Belgium | 9 |
| Egypt | 8 |
| Netherlands | 8 |
| Finland | 7 |
| Israel | 7 |
| Poland | 7 |
| Taiwan | 7 |
| India | 6 |
| Japan | 6 |
| Australia | 5 |
| Austria | 2 |
| Denmark|Sweden | 2 |
| Ecuador | 2 |
| France|Germany|Italy | 2 |
| Hong Kong | 2 |
| Indonesia | 2 |
| Iran, Islamic Republic of | 2 |
| Malaysia | 2 |
| Mexico | 2 |
| Pakistan | 2 |
| Portugal | 2 |
| Singapore | 2 |
| Slovenia | 2 |
| Thailand | 2 |
| Turkey | 2 |
| United States|Canada|Korea, Republic of | 2 |
| United States|Germany | 2 |
| Argentina | 1 |
| Argentina|Australia|Belgium|Croatia|France|Germany|Italy|Netherlands|Norway | 1 |
| Argentina|Bolivia|Brazil|Colombia|El Salvador | 1 |
| Austria|Belgium|United States|Argentina|Australia|Brazil|Canada|China|Czechia|Denmark|Finland|France|Germany|Grenada|Hungary|Ireland|Israel|Italy|Korea, Republic of|Netherlands|New Zealand|Poland|Puerto Rico|Slovakia|South Africa|Spain|Sweden|Switzerland|United Kingdom | 1 |
| Austria|France|Germany|Italy|Netherlands|Switzerland|United Kingdom | 1 |
| Austria|Germany|Switzerland | 1 |
| Austria|Netherlands|New Zealand | 1 |
| Belgium|Canada | 1 |
| Belgium|Denmark|Estonia|Finland|Germany|Ireland|Italy|Latvia|Netherlands|Norway|Poland|Sweden|United Kingdom | 1 |
| Belgium|Denmark|Finland|France|Germany|Hungary|Italy|Netherlands|Poland|Portugal|Russian Federation|Saudi Arabia|South Africa|Spain | 1 |
| Belgium|Germany|Israel|Sweden | 1 |
| Belgium|Italy|Netherlands | 1 |
| Belgium|United Kingdom | 1 |
| Bolivia | 1 |
| Botswana|Brazil|Cameroon|China|Egypt|Ethiopia|India|Kazakhstan|Kenya|Kyrgyzstan|Malawi|Mexico|Mozambique|Nepal|Nigeria|Pakistan|Paraguay|Philippines|Rwanda|South Africa|Sudan|Tanzania|Uganda|Zambia|Zimbabwe | 1 |
| Canada|Germany | 1 |
| China|Germany|Netherlands | 1 |
| China|Hong Kong | 1 |
| China|United States|Argentina|Australia|Belgium|Brazil|Bulgaria|Canada|Chile|Czechia|Denmark|Estonia|France|Germany|Greece|Hong Kong|Hungary|India|Italy|Japan|Korea, Republic of|Mexico|Netherlands|New Zealand|Norway|Pakistan|Peru|Philippines|Poland|Romania|Russian Federation|Slovakia|South Africa|Spain|Sweden|Taiwan|Thailand|Ukraine|United Kingdom | 1 |
| Colombia | 1 |
| Czech Republic | 1 |
| Denmark|Estonia|Finland|France|Norway|Spain|Sweden|United Kingdom | 1 |
| Denmark|Finland|Iceland|Norway|Sweden | 1 |
| Denmark|Netherlands|Spain | 1 |
| Denmark|Netherlands|Spain|Sweden | 1 |
| Denmark|Poland | 1 |
| Finland|France|Germany|Italy|Netherlands|Poland|Spain|Switzerland|United Kingdom | 1 |
| France|Germany|Italy|Poland|Spain|Sweden|United Kingdom | 1 |
| Germany|Italy|Korea, Republic of|Netherlands|Spain|Turkey | 1 |
| Greece | 1 |
| Hong Kong|Taiwan | 1 |
| Hungary|Malaysia|Poland | 1 |
| Jordan | 1 |
| Lithuania | 1 |
| Mauritius | 1 |
| Nepal | 1 |
| Netherlands|United States|Argentina|Australia|Bulgaria|Canada|Czechia|Denmark|France|Germany|Hungary|Italy|Korea, Republic of|Poland|Russian Federation|Spain|Sweden|Taiwan|United Kingdom | 1 |
| Palestinian Territory, occupied | 1 |
| Poland|United States|Australia|Canada|China|Czech Republic|Denmark|France|Hungary|Mexico|Netherlands|Spain|United Kingdom | 1 |
| Saudi Arabia | 1 |
| South Africa | 1 |
| Spain|United States|Argentina|Australia|Bulgaria|Canada|Denmark|Estonia|France|Germany|Hungary|India|Netherlands|New Zealand|Pakistan|Romania | 1 |
| Spain|United States|Australia|Austria|Belgium|Canada|France|Germany|Ireland|Italy|Netherlands|South Africa|Switzerland|United Kingdom| | 1 |
| Sri Lanka | 1 |
| Uganda | 1 |
| Ukraine | 1 |
| United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|China|Egypt|France|Germany|Hungary|India|Israel|Italy|Japan|Lithuania|Malaysia|Mexico|Netherlands|New Zealand|North Macedonia|Peru|Poland|Portugal|Romania|Russian Federation|Saudi Arabia|Serbia|Singapore|South Africa|Spain|Sweden|Switzerland|Taiwan|Thailand|United Kingdom | 1 |
| United States|Argentina|Australia|Austria|Brazil|Canada|Finland|France|Germany|Israel|Italy|Mexico|Russian Federation|Spain|United Kingdom | 1 |
| United States|Argentina|Brazil|Canada|Georgia|Russian Federation | 1 |
| United States|Australia|Belgium|Brazil|Canada|Czechia|Denmark|Ireland|Israel|Italy|Korea, Republic of|Netherlands|New Zealand|Portugal|Spain|United Kingdom | 1 |
| United States|Australia|Belgium|Canada|Denmark|Germany|Hungary|Israel|Korea, Republic of|Netherlands|New Zealand|Spain|Switzerland | 1 |
| United States|Australia|Brazil|Canada|China|Czechia|Denmark|France|Germany|Ireland|New Zealand|Poland|Taiwan|United Kingdom | 1 |
| United States|Australia|China|Czechia|Denmark|France|Poland|United Kingdom | 1 |
| United States|Austria|Belgium|Bulgaria|Canada|Czech Republic|Denmark|France|Germany|Hungary|Israel|Lebanon|Poland|Russian Federation|Spain|Sweden|United Kingdom | 1 |
| United States|Austria|Canada|China|Croatia|Germany|Italy|Japan|Korea, Republic of|Netherlands|Portugal|Serbia|Singapore | 1 |
| United States|Austria|Canada|Croatia|Egypt|France|Hungary|India|Israel|Lebanon|Spain|Turkey|Ukraine|United Kingdom | 1 |
| United States|Belgium|Canada|Netherlands|Poland|Spain | 1 |
| United States|Belgium|Denmark|Israel|Netherlands|South Africa|United Kingdom | 1 |
| United States|Brazil|Canada|Czechia|Italy | 1 |
| United States|Brazil|Canada|Denmark|Germany|Japan|Netherlands|Singapore | 1 |
| United States|Canada|China | 1 |
| United States|Canada|Czech Republic|Germany|Hungary|New Zealand|Norway|Slovakia|South Africa | 1 |
| United States|Canada|Czech Republic|Germany|South Africa|United Kingdom | 1 |
| United States|Canada|France | 1 |
| United States|Canada|Japan | 1 |
| United States|Canada|Mexico | 1 |
| United States|Colombia | 1 |
| United States|Czechia|Netherlands|United Kingdom | 1 |
| United States|Denmark|Germany|Israel|Netherlands | 1 |
| United States|France|Greece|Poland|United Kingdom | 1 |
| United States|Germany|Ireland | 1 |
| United States|Germany|Netherlands|New Zealand | 1 |
| United States|United Kingdom | 1 |
| Venezuela | 1 |
| Venezuela|United States|Argentina|Brazil|Chile|Colombia|Lithuania|Netherlands|Peru | 1 |
| Site_count | Study_Count |
|---|---|
| 1 | 909 |
| 2 | 64 |
| 3 | 29 |
| 4 | 12 |
| 5 | 17 |
| 6 | 6 |
| 7 | 6 |
| 8 | 4 |
| 9 | 9 |
| 10 | 8 |
| 11 | 3 |
| 12 | 8 |
| 13 | 5 |
| 14 | 2 |
| 15 | 2 |
| 16 | 7 |
| 17 | 6 |
| 18 | 2 |
| 19 | 4 |
| 20 | 3 |
| 22 | 1 |
| 23 | 3 |
| 24 | 2 |
| 27 | 2 |
| 28 | 2 |
| 29 | 1 |
| 30 | 2 |
| 31 | 1 |
| 33 | 1 |
| 34 | 2 |
| 38 | 1 |
| 39 | 1 |
| 41 | 1 |
| 45 | 1 |
| 46 | 1 |
| 47 | 1 |
| 48 | 1 |
| 51 | 1 |
| 54 | 1 |
| 55 | 1 |
| 57 | 1 |
| 62 | 1 |
| 64 | 1 |
| 73 | 1 |
| 80 | 1 |
| 81 | 1 |
| 82 | 1 |
| 91 | 1 |
| 92 | 1 |
| 102 | 1 |
| 119 | 1 |
| 120 | 1 |
| 124 | 1 |
| 147 | 1 |
| 153 | 1 |
| 157 | 1 |
| 159 | 1 |
| 177 | 1 |
| 241 | 1 |
| 270 | 1 |
| 314 | 1 |
| 320 | 1 |
| 471 | 1 |
| 651 | 1 |
| 1091 | 1 |
| Phase | Study_Count |
|---|---|
| N/A | 594 |
| Phase 3 | 229 |
| Phase 4 | 129 |
| Phase 2 | 117 |
| Phase 1 | 43 |
| Phase 2/Phase 3 | 19 |
| Phase 1/Phase 2 | 17 |
| Early Phase 1 | 10 |
| Number_of_Arms | Count_of_Studies |
|---|---|
| 1 | 182 |
| 2 | 587 |
| 3 | 106 |
| 4 | 33 |
| 5 | 5 |
| 6 | 10 |
| 11 | 1 |
| NA | 234 |
| Count of Versions | Count of Studies |
|---|---|
| 1 | 102 |
| 2 | 158 |
| 3 | 234 |
| 4 | 170 |
| 5 | 103 |
| 6 | 91 |
| 7 | 62 |
| 8 | 48 |
| 9 | 38 |
| 10 | 32 |
| 11 | 16 |
| 12 | 11 |
| 13 | 13 |
| 14 | 12 |
| 15 | 7 |
| 16 | 10 |
| 17 | 7 |
| 18 | 3 |
| 19 | 3 |
| 20 | 2 |
| 21 | 2 |
| 22 | 4 |
| 24 | 1 |
| 26 | 3 |
| 28 | 1 |
| 29 | 2 |
| 31 | 1 |
| 32 | 1 |
| 34 | 1 |
| 36 | 2 |
| 37 | 1 |
| 38 | 1 |
| 40 | 1 |
| 55 | 1 |
| 56 | 2 |
| 57 | 1 |
| 60 | 1 |
| 71 | 1 |
| 73 | 1 |
| 77 | 1 |
| 79 | 1 |
| 80 | 1 |
| 88 | 1 |
| 91 | 1 |
| 97 | 1 |
| 98 | 1 |
| 166 | 1 |
| Change Type | Count_of_Changes | Count_of_Studies | ratio |
|---|---|---|---|
| Study Status | 6123 | 1056 | 5.798296 |
| Contacts/Locations | 2430 | 791 | 3.072061 |
| Recruitment Status | 1360 | 801 | 1.697878 |
| None (earliest Version on record) | 1158 | 1158 | 1.000000 |
| Study Design | 1114 | 675 | 1.650370 |
| Outcome Measures | 838 | 489 | 1.713701 |
| Study Identification | 771 | 458 | 1.683406 |
| Study Description | 710 | 444 | 1.599099 |
| Sponsor/Collaborators | 696 | 466 | 1.493562 |
| Arms | 693 | 439 | 1.578588 |
| Interventions | 693 | 439 | 1.578588 |
| Eligibility | 600 | 395 | 1.518987 |
| Oversight | 443 | 348 | 1.272989 |
| References | 385 | 252 | 1.527778 |
| Conditions | 209 | 169 | 1.236686 |
| Results | 144 | 144 | 1.000000 |
| More Information | 139 | 80 | 1.737500 |
| IPDSharing | 99 | 94 | 1.053192 |
| Baseline Characteristics | 50 | 43 | 1.162791 |
| Results Submission Events | 46 | 46 | 1.000000 |
| Participant Flow | 31 | 27 | 1.148148 |
| Reported Adverse Events | 30 | 30 | 1.000000 |
| Documents | 22 | 18 | 1.222222 |
| 2020 Outcome Measures | 2 | 1 | 2.000000 |
| Quality Control Review has not concludedReturned: June 17 | 1 | 1 | 1.000000 |
| Quality Control Review has not concludedReturned: May 27 | 1 | 1 | 1.000000 |
| Measure | Early.Phase.1 | N.A | Phase.1 | Phase.1.Phase.2 | Phase.2 | Phase.2.Phase.3 | Phase.3 | Phase.4 |
|---|---|---|---|---|---|---|---|---|
| Min. | 5.0 | 1.0000 | 5.0000 | 17.00000 | 6.0000 | 18.0000 | 3.000 | 2.0000 |
| 1st Qu. | 20.0 | 48.5000 | 20.2500 | 26.00000 | 40.0000 | 49.5000 | 120.000 | 60.0000 |
| Median | 26.0 | 117.0000 | 33.5000 | 36.00000 | 90.0000 | 100.0000 | 255.000 | 130.0000 |
| Mean | 28.0 | 794.5617 | 285.7619 | 59.41176 | 285.7079 | 129.2105 | 1473.861 | 623.5039 |
| 3rd Qu. | 36.5 | 300.0000 | 90.0000 | 62.00000 | 216.0000 | 175.0000 | 902.000 | 441.0000 |
| Max. | 50.0 | 100000.0000 | 8400.0000 | 176.00000 | 8727.0000 | 375.0000 | 39876.000 | 8709.0000 |
| group_type | Group_Count |
|---|---|
| Experimental | 859 |
| Active Comparator | 516 |
| NA | 234 |
| Placebo Comparator | 210 |
| No Intervention | 162 |
| Other | 136 |
| Sham Comparator | 19 |
| intervention_model | Study_Count |
|---|---|
| Parallel Assignment | 699 |
| Single Group Assignment | 233 |
| NA | 122 |
| Crossover Assignment | 61 |
| Factorial Assignment | 32 |
| Sequential Assignment | 11 |
| primary_purpose | Study_Count |
|---|---|
| Treatment | 579 |
| Prevention | 278 |
| Diagnostic | 86 |
| Supportive Care | 53 |
| Basic Science | 44 |
| Other | 38 |
| Health Services Research | 35 |
| NA | 27 |
| Screening | 12 |
| Device Feasibility | 5 |
| Educational/Counseling/Training | 1 |
| Country | Study_Count |
|---|---|
| NA | 566 |
| United States | 199 |
| China | 29 |
| France | 29 |
| Germany | 29 |
| Korea, Republic of | 20 |
| United Kingdom | 19 |
| Canada | 13 |
| Italy | 12 |
| Belgium | 10 |
| Switzerland | 10 |
| Norway | 9 |
| Israel | 8 |
| Sweden | 8 |
| Austria | 7 |
| United States|Canada | 7 |
| Denmark | 6 |
| Russian Federation | 6 |
| Singapore | 5 |
| Spain | 5 |
| Brazil | 4 |
| Egypt | 4 |
| Poland | 4 |
| Finland | 3 |
| India | 3 |
| Japan | 3 |
| Netherlands | 3 |
| Croatia | 2 |
| United States|Australia | 2 |
| United States|United Kingdom | 2 |
| Austria|Belgium|Denmark|France|Germany|Hungary|Ireland|Italy|Netherlands|Spain|United Kingdom | 1 |
| Austria|Belgium|France|Germany|Italy|Norway|Poland|Slovenia|Spain|United Kingdom | 1 |
| Austria|Czech Republic|Germany|Switzerland|United Kingdom | 1 |
| Austria|Germany | 1 |
| Bangladesh | 1 |
| Belgium|Czechia|Germany|Italy|Netherlands|United Kingdom | 1 |
| Belgium|France|Germany|Greece|Ireland|Italy|Netherlands|Spain|Sweden | 1 |
| Belgium|France|Germany|Hungary|Ireland|Italy|Latvia|Poland|Spain|United Kingdom | 1 |
| Belgium|France|Germany|Italy|Switzerland | 1 |
| Belgium|Germany|Ireland|Italy|Switzerland | 1 |
| Belgium|Singapore | 1 |
| Brazil|Germany|Italy|United Kingdom | 1 |
| Bulgaria | 1 |
| Czech Republic | 1 |
| Czechia|France|Germany|Italy|Netherlands|United Kingdom | 1 |
| Ecuador | 1 |
| Fiji|New Caledonia|United Kingdom | 1 |
| Germany|India|Sri Lanka | 1 |
| Germany|Italy|Portugal|Spain | 1 |
| Greece | 1 |
| Hong Kong | 1 |
| Hungary | 1 |
| Kenya | 1 |
| Nicaragua | 1 |
| Nigeria|Uganda | 1 |
| Peru|Switzerland | 1 |
| Portugal | 1 |
| Puerto Rico | 1 |
| Qatar | 1 |
| Spain|Sweden | 1 |
| Taiwan | 1 |
| Turkey | 1 |
| United States|Argentina|Australia|Belgium|Canada|France|India|Italy|Japan|Malta|Netherlands|Norway|Sweden|Switzerland|Taiwan | 1 |
| United States|Australia|Belgium|Canada|Denmark|France|Germany|Hong Kong|Ireland|Italy|Netherlands|Spain|United Kingdom | 1 |
| United States|Austria|Belgium|Canada|France|Germany|Italy|Poland|Spain|Switzerland|United Kingdom | 1 |
| United States|Nigeria|Thailand | 1 |
| Zambia | 1 |
| Site_count | Study_Count |
|---|---|
| 1 | 948 |
| 2 | 38 |
| 3 | 9 |
| 4 | 13 |
| 5 | 10 |
| 6 | 6 |
| 7 | 5 |
| 8 | 1 |
| 9 | 3 |
| 10 | 4 |
| 12 | 2 |
| 13 | 2 |
| 14 | 3 |
| 15 | 1 |
| 16 | 1 |
| 17 | 3 |
| 23 | 1 |
| 24 | 1 |
| 25 | 1 |
| 29 | 1 |
| 32 | 1 |
| 33 | 1 |
| 37 | 2 |
| 40 | 2 |
| 43 | 1 |
| 47 | 1 |
| 80 | 1 |
| 88 | 1 |
| 183 | 1 |
| Count of Versions | Count of Studies |
|---|---|
| 1 | 83 |
| 2 | 199 |
| 3 | 391 |
| 4 | 137 |
| 5 | 73 |
| 6 | 31 |
| 7 | 28 |
| 8 | 26 |
| 9 | 15 |
| 10 | 12 |
| 11 | 12 |
| 12 | 8 |
| 13 | 5 |
| 14 | 3 |
| 15 | 2 |
| 16 | 4 |
| 17 | 3 |
| 18 | 1 |
| 19 | 4 |
| 20 | 1 |
| 21 | 3 |
| 22 | 1 |
| 23 | 1 |
| 24 | 2 |
| 25 | 2 |
| 30 | 2 |
| 31 | 1 |
| 34 | 1 |
| 36 | 1 |
| 45 | 1 |
| 47 | 1 |
| 55 | 1 |
| 83 | 2 |
| 97 | 1 |
| 119 | 1 |
| 124 | 1 |
| 142 | 1 |
| 157 | 1 |
| 170 | 1 |
| 527 | 1 |
| Change Type | Count_of_Changes | Count_of_Studies | ratio |
|---|---|---|---|
| Study Status | 4947 | 981 | 5.042814 |
| None (earliest Version on record) | 1064 | 1064 | 1.000000 |
| Study Description | 1046 | 448 | 2.334821 |
| Study Identification | 1011 | 642 | 1.574766 |
| Study Design | 944 | 622 | 1.517685 |
| Contacts/Locations | 888 | 452 | 1.964602 |
| Eligibility | 745 | 596 | 1.250000 |
| Recruitment Status | 737 | 539 | 1.367347 |
| Sponsor/Collaborators | 477 | 371 | 1.285714 |
| References | 363 | 208 | 1.745192 |
| Outcome Measures | 306 | 232 | 1.318966 |
| Oversight | 270 | 234 | 1.153846 |
| Groups | 187 | 139 | 1.345324 |
| Interventions | 187 | 139 | 1.345324 |
| Conditions | 124 | 88 | 1.409091 |
| IPDSharing | 53 | 52 | 1.019231 |
| More Information | 18 | 11 | 1.636364 |
| Results | 18 | 18 | 1.000000 |
| Results Submission Events | 11 | 11 | 1.000000 |
| Documents | 5 | 5 | 1.000000 |
| Baseline Characteristics | 4 | 4 | 1.000000 |
| Reported Adverse Events | 4 | 4 | 1.000000 |
| Participant Flow | 3 | 3 | 1.000000 |
| Measure | Observational |
|---|---|
| Min | 1.0 |
| 1st Qu | 89.5 |
| Median | 314.0 |
| Mean | 225022.3 |
| 3rd Qu | 1500.0 |
| Max | 99999999.0 |
| observational_model | Study_Count |
|---|---|
| NA | 483 |
| Cohort | 371 |
| Case-Only | 68 |
| Case-Control | 41 |
| Case Control | 33 |
| Other | 28 |
| Family-Based | 12 |
| Ecologic or Community | 10 |
| Case-Crossover | 6 |
| Defined Population, Natural History | 6 |
| Defined Population | 3 |
| Natural History | 3 |
| time_perspective | Study_Count |
|---|---|
| NA | 443 |
| Prospective | 422 |
| Retrospective | 93 |
| Cross-Sectional | 86 |
| Other | 10 |
| Longitudinal, Prospective | 5 |
| Longitudinal, Retrospective/Prospective | 2 |
| Cross-Sectional, Prospective | 1 |
| Cross-Sectional, Retrospective | 1 |
| Longitudinal, Retrospective | 1 |
| Country | Study_Count |
|---|---|
| NA | 11 |
| China | 10 |
| France | 7 |
| United States | 6 |
| Italy | 4 |
| Korea, Republic of | 3 |
| Austria | 2 |
| Belgium | 2 |
| Egypt | 2 |
| Germany | 2 |
| Hong Kong | 2 |
| Netherlands | 2 |
| Russian Federation | 2 |
| Spain | 2 |
| Switzerland | 2 |
| Austria|Germany | 1 |
| Brazil | 1 |
| Canada | 1 |
| Colombia | 1 |
| Denmark | 1 |
| France|Germany|Italy|Lithuania|Switzerland | 1 |
| Greece | 1 |
| Israel | 1 |
| Netherlands|Poland|Spain|United Kingdom | 1 |
| Norway | 1 |
| Portugal|Spain | 1 |
| Rwanda | 1 |
| Singapore | 1 |
| Thailand | 1 |
| United States|Australia|Canada|China|India|Korea, Republic of|Nepal|Russian Federation|Saudi Arabia|Ukraine | 1 |
| United States|Austria | 1 |
| United States|Canada|Germany|Israel | 1 |
| United States|Canada|United Kingdom | 1 |
| United States|Israel | 1 |
| Site_count | Study_Count |
|---|---|
| 1 | 58 |
| 2 | 1 |
| 3 | 3 |
| 4 | 3 |
| 6 | 1 |
| 7 | 1 |
| 10 | 1 |
| 13 | 1 |
| 16 | 1 |
| 18 | 1 |
| 20 | 1 |
| 22 | 1 |
| 28 | 1 |
| 36 | 1 |
| 44 | 1 |
| 59 | 1 |
| 67 | 1 |
| Count of Versions | Count of Studies |
|---|---|
| 1 | 22 |
| 2 | 18 |
| 3 | 5 |
| 4 | 15 |
| 5 | 3 |
| 6 | 2 |
| 7 | 2 |
| 8 | 2 |
| 9 | 3 |
| 11 | 1 |
| 12 | 3 |
| 14 | 1 |
| 28 | 1 |
| Change Type | Count_of_Changes | Count_of_Studies | ratio |
|---|---|---|---|
| Study Status | 227 | 56 | 4.053571 |
| Contacts/Locations | 98 | 39 | 2.512821 |
| None (earliest Version on record) | 78 | 78 | 1.000000 |
| Recruitment Status | 47 | 35 | 1.342857 |
| Study Description | 37 | 19 | 1.947368 |
| Study Design | 34 | 22 | 1.545454 |
| Outcome Measures | 17 | 13 | 1.307692 |
| Eligibility | 16 | 14 | 1.142857 |
| Study Identification | 13 | 12 | 1.083333 |
| Oversight | 11 | 10 | 1.100000 |
| Groups | 10 | 9 | 1.111111 |
| Interventions | 10 | 9 | 1.111111 |
| Conditions | 7 | 6 | 1.166667 |
| References | 6 | 5 | 1.200000 |
| Sponsor/Collaborators | 6 | 6 | 1.000000 |
| IPDSharing | 4 | 4 | 1.000000 |
| Documents | 2 | 1 | 2.000000 |
| Results | 1 | 1 | 1.000000 |
| Results Submission Events | 1 | 1 | 1.000000 |
| Measure | Registries |
|---|---|
| Min | 1.0 |
| 1st Qu | 150.0 |
| Median | 645.0 |
| Mean | 107744.4 |
| 3rd Qu | 2000.0 |
| Max | 5940299.0 |
| observational_model | Study_Count |
|---|---|
| Cohort | 58 |
| Case-Only | 12 |
| Case-Control | 5 |
| Other | 3 |
| time_perspective | Study_Count |
|---|---|
| Prospective | 70 |
| Cross-Sectional | 4 |
| Other | 3 |
| Retrospective | 1 |
| target_duration | Study_Count |
|---|---|
| 5 Years | 11 |
| 2 Years | 10 |
| 1 Year | 9 |
| 10 Years | 6 |
| 12 Months | 6 |
| 1 Day | 5 |
| 24 Months | 4 |
| 3 Years | 3 |
| 6 Months | 3 |
| 1 Month | 2 |
| 2 Months | 2 |
| 20 Years | 2 |
| 3 Months | 2 |
| 10 Days | 1 |
| 15 Months | 1 |
| 15 Years | 1 |
| 17 Years | 1 |
| 18 Years | 1 |
| 2 Days | 1 |
| 3 Days | 1 |
| 36 Months | 1 |
| 4 Weeks | 1 |
| 4 Years | 1 |
| 6 Years | 1 |
| 7 Days | 1 |
| 9 Months | 1 |